|
Advocate Angle
February is Cancer Prevention Month:
Steps We Can Take Today for a Healthier Tomorrow
| |
Written by Eva Villalba, an NRG Oncology Patient Advocate Committee Member | |
February is Cancer Prevention Month, a time to highlight the importance of preventative measures in reducing cancer rates. I’ve been working as a Patient Advocate since 2008, and am the Executive Director of one of the most influential Patient Advocacy groups in Canada, the Quebec Cancer Coalition, where we have been working tirelessly to improve the lives of people affected by cancer but also to reduce avoidable cancers, raise awareness and advocate for effective cancer prevention strategies. | |
|
NRG Study News & New Protocols Under Development | |
New Protocols Under Development | |
|
NRG Opens First Pragmatic and Streamlined Trial: One Versus Two Years of Maintenance Olaparib for Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer (NRG-GY036)
| |
During the NRG Oncology 2025 Winter Meeting in January, NRG Oncology activated the NRG-GY036 clinical study: the group’s first pragmatic study conducted in a real-world clinical practice setting with streamlined data collection. NRG-GY036 is a phase III study comparing the difference between one year and two years of maintenance Olaparib, with or without bevacizumab, in patients with BRCA1/2 mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy. | |
Protocol Support Committee (PSC) Column | |
NRG Oncology PSC 2025 Winter Meeting Wrap Up | |
|
Written by: Erin McCaig RN, BSN from Cancer Research for the Ozarks
On behalf of the Protocol Support Committee (PSC), we would like to thank everyone who attended the NRG Oncology Semiannual Meeting in balmy Phoenix. There were 134 in-person attendees and 187 virtual attendees at the PSC Nurse/CRA Introduction to Clinical Trials: Principles of Clinical Trial Management Thursday morning. There were 72 in-person attendees and 122 virtual attendees at the afternoon Introductions to Clinical Trials Discussion Sessions. Our Friday morning PSC Continuing Education Sessions saw 108 in-person attendees and 166 virtual attendees.
| |
|
NRG Oncology Partners with TravaLab to offer Mobile Phlebotomy
| |
FORTE is offering sites the opportunity to implement remote blood draws with participants enrolled in NRG-CC005. NRG Oncology is working with TravaLab, an online portal that offers mobile phlebotomy services nationwide, to conduct blood draws for FORTE. This process will complement remote consent processes at all participating sites to increase overall accrual to NRG-CC005. | |
A Message from the NRG Oncology Group Chairs
| |
Last week, our NRG Oncology Group Chairs issued a message regarding the current concerns as well as highlighting the value in clinical research. | |
|
New NRG Oncology Podcast Episode! | |
Our first podcast episode of February takes a look at the NRG-BR008 “HERO” study for patients with low-risk HER2-positive breast cancer. Our co-hosts sit with trial Co-PIs Drs. Lior Braunstein and Melissa Mitchell to take a deeper dive into the study and what investigators should know. Listen on Apple Podcasts, Spotify, Amazon/Audible, and YouTube. | |
NRG Oncology has recently added Bluesky to our portfolio of social media platforms. If you are currently on Bluesky, follow us at @nrgonc.bsky.social for all of our updates. | |
|
What is Bluesky? Bluesky is an easy-to-use, open network social media microblogging service. This platform is similar to the original Twitter platform (now X) where users can share short posts with text, images, and videos as well send direct messages and a variety of other engagement activities. | |
Radiotherapy with cetuximab may be superior to radiotherapy alone for selected patients who underwent surgery for head and neck cancer | |
Recent results from the phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) showed that radiotherapy with cetuximab demonstrated superiority as measured by improved disease-free survival, a secondary endpoint. The study also showed no increase in long-term toxicity. The trial results, however, did not show a statistically significant improvement in overall survival, the primary endpoint. | |
|
Current NRG Oncology Group Chairs Re-Elected
| |
During the NRG Oncology 2025 Winter Meeting in Phoenix, NRG Voting PI Members voted to re-elect our current Group Chairs for another term. Drs. Quynh-Thu Le, Robert Mannel, and Norman Wolmark will continue to spearhead the Group’s ongoing efforts for the next six years. We are very appreciative of all they have accomplished to advance NRG's research and look forward to their continued guidance as NRG Oncology makes strides in reaching our research priorities and goals. | |
|
Dr. Knoll Receives Trailblazers in Health Care Award
| |
Congratulations to Dr. Miriam Knoll, NRG Oncology Communications Committee Member and Communications and Digital Engagement Workshop Co-Chair on being named a 2025 recipient of the Trailblazers in Health Care Award by City & State New York. Dr. Knoll is a Radiation Oncologist at Northwell Health and is the co-founder and CEO of the Jewish Orthodox Women’s Medical Association. Read more | |
|
#NRG2025 Winter Meeting Recap | |
|
Relive the NRG Oncology Winter Meeting in Phoenix by checking out our registrant emails that recapped and highlighted sessions and ongoing meeting activities:
Slides and other materials continue being added to our NRG Meeting webpages. Keep checking back as items are updated.
You can also experience the conversations that occurred by following our hashtag #NRG2025 on social media.
Save the date for our #NRG2025 Summer Meeting in Washington DC!
| | | | |
